Long-Term Assets: The sum of all assets classified as non-current.
Interpace Biosciences, Inc. (IDXG) had Long-Term Assets of $23.94M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$9.22M |
|
$22.66M |
|
$3.18M |
|
$6.04M |
|
$7.65M |
|
$1.58M |
|
$-0.04M |
|
$1.53M |
|
$1.53M |
|
$22.75M |
|
$22.75M |
|
$22.66M |
|
$22.75M |
|
$1.58M |
|
$1.81M |
|
4.42M |
|
27.70M |
|
$5.11 |
|
$0.94 |
|
| Balance Sheet Financials | |
$9.90M |
|
$1.42M |
|
|
Long-Term Assets |
$23.94M |
$33.84M |
|
$5.10M |
|
-- |
|
$6.37M |
|
$11.47M |
|
$22.36M |
|
$22.36M |
|
$22.36M |
|
4.43M |
|
| Cash Flow Statement Financials | |
$5.83M |
|
$-0.36M |
|
$-4.43M |
|
$1.46M |
|
$2.50M |
|
$1.04M |
|
$0.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.94 |
|
-- |
|
-- |
|
-- |
|
-- |
|
65.53% |
|
17.11% |
|
17.11% |
|
-- |
|
16.64% |
|
245.60% |
|
$5.47M |
|
-- |
|
-- |
|
-- |
|
0.27 |
|
-- |
|
1.63 |
|
55.11 |
|
101.74% |
|
101.74% |
|
67.24% |
|
101.74% |
|
$5.05 |
|
$0.20 |
|
$0.21 |
|